This center treats primary substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
Offering intensive care with 24/7 monitoring, residential treatment is typically 30 days and can cover multiple levels of care. Length can range from 14 to 90 days typically.
Recovery.com has connected directly with this treatment provider to validate the information in their profile.
This center treats primary substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
Offering intensive care with 24/7 monitoring, residential treatment is typically 30 days and can cover multiple levels of care. Length can range from 14 to 90 days typically.
We accept Medicaid plans, certain types of commercial insurance, and can assist with county funding.
Located in West Chester, Pennsylvania, Gaudenzia’s Kindred House is a residential facility for women struggling with substance use that allows women to bring their children along with them during treatment. Women receive trauma-informed, culturally sensitive, and gender-responsive care while having peace of mind that they will not lose custody of their children by seeking treatment. Participants engage in evidence-based individual and group counseling during their stay, which typically lasts 30-90 days.
Gaudenzia is committed to assisting underserved populations regardless of circumstances. They accept medicaid as well as some commercial insurance and are able to assist with county funding when needed.
This center treats primary substance use disorders and co-occurring mental health conditions. Your treatment plan addresses each condition at once with personalized, compassionate care for comprehensive healing.
CARF stands for the Commission on Accreditation of Rehabilitation Facilities. It's an independent, non-profit organization that provides accreditation services for a variety of healthcare services. To be accredited means that the program meets their standards for quality, effectiveness, and person-centered care.
Medication-Assisted Treatment (MAT) is an evidence-based approach that pairs FDA-approved medications with counseling to treat addiction. The medications are used to reduce cravings, ease withdrawal symptoms, or block the effects of substances. More about MAT
Dolophine®, Methadose®
Methadone is a full opioid agonist, meaning it activates opioid receptors in the brain to produce effects like pain relief and euphoria. It is longer acting than many other opioids, making it useful in medication-assisted treatment for opioid use disorder.
It reduces withdrawal symptoms and cravings by occupying opioid receptors without causing intense highs. Because it is a full agonist, it must be used carefully to avoid overdose, but it is highly effective when taken as prescribed within a structured program.
Vivitrol®, Revia®
Naltrexone is an opioid antagonist, meaning it blocks opioid receptors in the brain and prevents opioids from producing effects like euphoria or sedation. It is used to treat both opioid and alcohol use disorders, but does not cause physical dependence or withdrawal.
It helps reduce cravings and the rewarding effects of opioids or alcohol, supporting long-term recovery. Because it blocks opioid effects, it should only be started after a person has fully detoxed from opioids to avoid triggering withdrawal.
Suboxone®, Subutex®, Sublocade®, Zubsolv®
Buprenorphine is a partial opioid agonist used to treat opioid use disorder. It activates opioid receptors to reduce cravings and withdrawal but has a ceiling effect, meaning it produces less euphoria and respiratory depression than full opioids.
Buprenorphine binds tightly to opioid receptors, blocking other opioids from attaching and reducing the risk of misuse. It's often combined with naloxone (as in Suboxone®) to discourage injection misuse and is available in daily or monthly forms.